Physician profile
Benjamin Z Egger
NPI 1881076347
$4,200.83
in general payments reported to CMS, 2019-2025
27 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $579 · 2021: $1,188 · 2022: $552 · 2023: $345 · 2024: $571 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,706.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,210.84 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $713.07 | 2020-2025 | Qulipta, Dalvance, Botox |
| Novo Nordisk INC | $633.76 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $268.17 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $239.89 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $157.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $144.81 | 2019-2022 | |
| Allergan, INC. | $126.25 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.84 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.23 | 2021-2023 | Xifaxan |
| Philips North America LLC | $74.97 | 2023 | |
| Medtronic, INC. | $67.28 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $56.83 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $43.15 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $37.10 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $26.01 | 2021-2022 | |
| Abbott Laboratories | $24.74 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $24.28 | 2025 | Rexulti |
| Bausch Health US, LLC | $20.62 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.43 | 2024 | Nuzyra |
| Boston Scientific Corporation | $18.39 | 2024 | Watchman Flx |
| Organon LLC | $16.47 | 2021 | |
| Vapotherm INC | $15.95 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2025 | |
| Merck Sharp & Dohme LLC | $14.03 | 2022 | |
| Corcept Therapeutics | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Egger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.